Mayesta

Isotretinoin, the active ingredient in Mayesta, is a retinoid presented as an oral formulation for oral use. It is prescribed for severe nodular acne and acne vulgaris in patients who have not responded to conventional therapies. The drug is formulated to meet European Union pharmaceutical standards and is distributed under a prescription‑only status.

GNH USA supplies Mayesta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to Good Distribution Practice, ensuring product integrity during storage and transport across global markets.

Isotretinoin is a systemic retinoid that targets severe acne disorders by modulating skin cell growth and sebum production.

- Severe nodular acne: reduces inflammatory nodules and prevents formation of new lesions. - Acne vulgaris: decreases both inflammatory and non‑inflammatory lesions, improving overall skin appearance. - Recalcitrant acne: provides therapeutic benefit when standard topical and oral antibiotics have failed.

Isotretinoin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dry skin and mucous membranes - Cheilitis (cracked lips) - Dry eyes or irritation - Elevated triglyceride levels - Transient headache - Skin peeling or desquamation

Serious or Rare Side Effects: - Severe depression or suicidal ideation - Pancreatitis - Significant liver injury - Pseudotumor cerebri (intracranial hypertension) - Teratogenic birth defects - Stevens‑Johnson syndrome or toxic epidermal necrolysis

Before initiating isotretinoin therapy, several precautions should be observed to minimize risks. - Pregnancy contraindication: drug is classified as Category X and must not be used during pregnancy. - Contraception requirement: women of childbearing potential must use effective contraception throughout treatment and for one month after discontinuation. - Liver function monitoring: obtain baseline liver enzymes and repeat periodically during therapy. - Lipid profile monitoring: assess baseline triglycerides and cholesterol, repeat as needed. - Vitamin A intake restriction: avoid concurrent high‑dose vitamin A supplements. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Isotretinoin can interact with other medicines, affecting safety or effectiveness.

Major Interactions (Avoid): - Tetracycline antibiotics: combined use increases risk of intracranial hypertension. - Vitamin A supplements: additive toxicity may lead to severe hypervitaminosis A. - Phenobarbital and other enzyme inducers: may reduce isotretinoin plasma levels, diminishing efficacy.

Moderate Interactions (Monitor Closely): - Oral contraceptives: isotretinoin may reduce hormonal contraceptive effectiveness; additional barrier methods are advised. - Anticonvulsants (e.g., carbamazepine, phenytoin): may lower isotretinoin concentrations, requiring monitoring. - Statins: concurrent use may increase risk of liver enzyme elevation; monitor hepatic function.